<?xml version="1.0" encoding="UTF-8"?>
<p>Eligible patients were 45 years of age or older with osteoarthritis in one or both knees for more than three months. The disease was diagnosed according to the American College of Rheumatology criteria [
 <xref rid="B24" ref-type="bibr">24</xref>] with radiographic confirmation (Kellgren–Lawrence grade 2 or higher). Patients were eligible for inclusion if they had osteoarthritic knee pain of at least moderate intensity (defined as a pain score of ≥35 mm at baseline on a 100 mm visual analog scale (VAS)) [
 <xref rid="B25" ref-type="bibr">25</xref>]. Patients were excluded if they also had any other underlying arthritis (e.g., rheumatoid arthritis or gouty arthritis), signs or symptoms of active inflammation at the knee, a condition requiring knee surgery in the next few months, or a recent knee injury; had used intra-articular corticosteroid injections in the previous six weeks; had used symptomatic slow-acting drugs for osteoarthritis (e.g., glucosamine sulfate or chondroitin sulfate) within the previous four months or had discontinued those drugs for less than six months; had a history of an allergic reaction to oral NSAIDs or herbal ingredients in THF-6; or had a history of gastrointestinal ulcer, perforation, or hemorrhage. Other exclusion criteria were pregnancy or lactation and any clinically significant abnormalities of blood chemistry (including serum uric acid of &gt;9 mg/dL) or other hematological parameters.
</p>
